A common vitamin may be the key to treating a "silent" global epidemic. With roughly 30% of the world’s population currently living with metabolic-associated fatty liver disease (MASLD)—a condition often fueled by obesity and type 2 diabetes—scientists have long been searching for a way to stop its progression toward permanent liver damage.
A new study led by researchers at UNIST, Pusan National University, and Ulsan University Hospital has pinpointed a specific "molecular switch" that drives the disease: a small RNA molecule called miR-93.
The Molecular Saboteur: How miR-93 Hijacks the Liver
MicroRNAs typically help fine-tune gene activity, but in cases of MASLD, miR-93 goes rogue. Researchers found that levels of this molecule skyrocket in response to modern diets high in fat and fructose.
When miR-93 levels are too high, it creates a metabolic "perfect storm" by:
- Blocking SIRT1: This crucial gene acts as the liver's energy regulator. When silenced by miR-93, the liver stops burning fat and starts storing it.
- Disrupting Energy Sensors: It dampens the LKB1-AMPK signaling pathway, the system that tells cells how to handle energy stress.
- Promoting Cholesterol: It shifts the liver’s chemistry to favor the production of cholesterol over the breakdown of fatty acids.
In lab tests, mice engineered to lack miR-93 remained remarkably healthy and lean-livered, even when fed a high-fat diet, proving that this single molecule is a primary driver of the disease.
Niacin: The Surprising Candidate
After screening 150 FDA-approved drugs, the research team discovered that niacin (vitamin B3) was the most effective compound at "turning off" the miR-93 switch.
By lowering miR-93, niacin restored the liver's natural ability to burn fat and improved mitochondrial health. Because niacin is already a staple treatment for high cholesterol, it is a prime candidate for "drug repurposing"—taking a known, safe medication and applying it to a new problem.
"Given that niacin is a well-established and safe medication... it holds promise as a candidate for combination therapies targeting miRNA pathways in MASLD," the research team noted.
From the Lab to the Clinic
While the results in mice are groundbreaking, scientists are now moving to human trials to confirm if vitamin B3 can truly shift fat away from the human liver.
A randomized clinical trial is currently underway at the Université de Sherbrooke to examine exactly how niacin influences fat distribution in MASLD patients. If successful, this "unexpected target" could turn a common supplement into a vital tool for millions of people worldwide.
0 Comments